Valneva SE
PAR: VLA.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Lingelbach
- Employees
- 713
- Headquarters
- Saint-Herblain, France
- IPO year
- 2007
- Market cap
- €413.0M
- Website
- https://valneva.com
Loading VLA…
Loading profile data…Frequently asked questions about VLA
What does Valneva SE (VLA.PA) do?
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis;...
Where does VLA.PA trade?
Valneva SE (VLA.PA) trades on the Euronext Paris.
What sector is VLA.PA in?
Valneva SE (VLA.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Valneva SE?
Thomas Lingelbach is the chief executive officer of Valneva SE (VLA.PA).
Where is Valneva SE headquartered?
Valneva SE is headquartered in France.
Does VLA.PA pay a dividend?
Valneva SE (VLA.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VLA.PA go public?
Valneva SE (VLA.PA) completed its initial public offering in 2007.